SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Therapeutics (CTIC)
CTIC 9.0900.0%Jun 26 5:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Ian@SI5/25/2006 1:07:37 PM
   of 946
 
Pix and Xyotax at ASCO next weekend...

Cell Therapeutics, Inc. Announces ASCO Activities

prnews

SEATTLE, May 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq: CTIC) today announced presentations of data on its development
candidates, XYOTAX(TM) (paclitaxel poliglumex), pixantrone, and CT-2106 at the
American Society of Clinical Oncology's 2005 Annual Meeting, held June 2-6 in
Atlanta, Georgia.

For a complete list of the CTI activities at ASCO, please see the table
below.


Date Time Abstract Title
#

Sat., June 3 8:00 AM 7578 Comparative trial of BBR 2778
poster (pixantrone) + rituximab vs. single
agent rituximab in the treatment of
relapsed/refractory indolent
non-Hodgkin's lymphoma (NHL)

Sat., June 3 8:00 AM 7039 Effect of gender on outcome in two
poster randomized phase III trials of
Noon paclitaxel poliglumex (PPX) in
discussion chemo-naive patients with advanced
NSCLC and poor performance status
(PS2)

Sat., June 3 8:00 AM 7040 Analysis of prognostic factors in
poster patients with advanced
Noon relapsed/refractory NSCLC: Cox
discussion regression analysis of a randomized
phase III trial comparing docetaxel
and paclitaxel poliglumex (PPX)

Sun., June 4 8:00 AM 7113 Analysis of prognostic factors in
poster chemo-naive patients with advanced
NSCLC and poor performance status
(PS): Cox regression analysis of two
phase III trials

Sun., June 4 2:00 PM 2015 Phase I trial of CT-2106
poster (polyglutamated camptothecin)
5:00 PM administered weekly in patients with
discussion advanced solid tumors



For more information about the ASCO annual meeting, please refer to the
conference website at asco.org.

In addition, CTI is a co-sponsor of the annual meeting of Women Against
Lung Cancer. The plenary session includes presentation from John E.
Niederhuber, M.D., Deputy Director, NCI, on NCI's plans for lung cancer and a
panel discussion on estrogen and lung cancer including Jill M. Siegfried,
Ph.D., from the University of Pittsburg Cancer Institute and Margaret Spitz,
M.D., MPH, from The University of Texas M. D. Anderson Cancer Center. For more
information, please refer to their website at
womenagainstlungcancer.org.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext